S&P 500   3,977.26 (+0.16%)
DOW   32,444.02 (+0.64%)
QQQ   308.34 (-0.82%)
AAPL   158.41 (-1.15%)
MSFT   276.58 (-1.42%)
META   202.52 (-1.69%)
GOOGL   102.51 (-2.78%)
AMZN   97.33 (-0.82%)
TSLA   191.33 (+0.48%)
NVDA   265.75 (-0.76%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.16 (-1.83%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.96 (-1.96%)
CGC   1.89 (-0.79%)
GE   93.23 (+2.04%)
DIS   95.10 (+1.08%)
AMC   4.39 (-1.79%)
PFE   40.31 (-0.20%)
PYPL   73.61 (-0.37%)
NFLX   326.69 (-0.52%)
S&P 500   3,977.26 (+0.16%)
DOW   32,444.02 (+0.64%)
QQQ   308.34 (-0.82%)
AAPL   158.41 (-1.15%)
MSFT   276.58 (-1.42%)
META   202.52 (-1.69%)
GOOGL   102.51 (-2.78%)
AMZN   97.33 (-0.82%)
TSLA   191.33 (+0.48%)
NVDA   265.75 (-0.76%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.16 (-1.83%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.96 (-1.96%)
CGC   1.89 (-0.79%)
GE   93.23 (+2.04%)
DIS   95.10 (+1.08%)
AMC   4.39 (-1.79%)
PFE   40.31 (-0.20%)
PYPL   73.61 (-0.37%)
NFLX   326.69 (-0.52%)
S&P 500   3,977.26 (+0.16%)
DOW   32,444.02 (+0.64%)
QQQ   308.34 (-0.82%)
AAPL   158.41 (-1.15%)
MSFT   276.58 (-1.42%)
META   202.52 (-1.69%)
GOOGL   102.51 (-2.78%)
AMZN   97.33 (-0.82%)
TSLA   191.33 (+0.48%)
NVDA   265.75 (-0.76%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.16 (-1.83%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.96 (-1.96%)
CGC   1.89 (-0.79%)
GE   93.23 (+2.04%)
DIS   95.10 (+1.08%)
AMC   4.39 (-1.79%)
PFE   40.31 (-0.20%)
PYPL   73.61 (-0.37%)
NFLX   326.69 (-0.52%)
S&P 500   3,977.26 (+0.16%)
DOW   32,444.02 (+0.64%)
QQQ   308.34 (-0.82%)
AAPL   158.41 (-1.15%)
MSFT   276.58 (-1.42%)
META   202.52 (-1.69%)
GOOGL   102.51 (-2.78%)
AMZN   97.33 (-0.82%)
TSLA   191.33 (+0.48%)
NVDA   265.75 (-0.76%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.16 (-1.83%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.96 (-1.96%)
CGC   1.89 (-0.79%)
GE   93.23 (+2.04%)
DIS   95.10 (+1.08%)
AMC   4.39 (-1.79%)
PFE   40.31 (-0.20%)
PYPL   73.61 (-0.37%)
NFLX   326.69 (-0.52%)
Lowest-Rated Stocks  
NYSE:GSK

GSK - GSK Stock Forecast, Price & News

$35.04
+0.66 (+1.92%)
(As of 03/27/2023 01:04 PM ET)
Add
Compare
Today's Range
$34.68
▼
$35.13
50-Day Range
$33.50
▼
$36.43
52-Week Range
$28.47
▼
$46.97
Volume
1.88 million shs
Average Volume
3.71 million shs
Market Capitalization
$75.53 billion
P/E Ratio
4.08
Dividend Yield
3.80%
Price Target
N/A

GSK MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.19% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
0.45mentions of GSK in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
4.83%
From $3.52 to $3.69 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

208th out of 995 stocks

Pharmaceutical Preparations Industry

85th out of 482 stocks

See Top Rated MarketRank™ Stocks Here

GSK stock logo

About GSK (NYSE:GSK) Stock

GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical company headquartered in Brentford, London. It operates in three main business areas: pharmaceuticals, vaccines and consumer healthcare products. The company has a global presence, operating in over 150 countries and employing over 94,000 people worldwide.

GSK has a long history of innovation and has been responsible for developing some of the world's most important medicines, including treatments for asthma, HIV/AIDS and cancer. The company is also committed to global health initiatives, focusing on improving access to essential medicines in developing countries.

Emma Walmsley has been the CEO of GSK since 2017, becoming the first female CEO of a major pharmaceutical company. She has been instrumental in transforming the company's operations and has led a significant restructuring effort to simplify the business and focus on key growth areas. The management team includes several other key executives, including Dr. Hal Barron, former President of Research and Development, now a Non-Executive Director and Luke Miels, Chief Commercial Officer.

GSK's financial performance has been mixed in recent years. The company's revenue has been relatively flat over the past few years, and rising R&D costs and the impact of COVID-19 on sales have impacted profitability. In Q2 - Q4 of 2022, the company's stock price dropped nearly 40% concerning long-term shareholders. This stock has underperformed the broader market and many of its peers in the pharmaceutical industry. However, this also points to the fact that the stock is undervalued relative to its peers providing good value for would-be investors.

GSK has also undergone significant changes in ownership in recent years. In 2019, the company merged its consumer healthcare business with Pfizer's consumer healthcare business to create a new joint venture. GSK owns a majority stake in the joint venture, which is expected to generate significant cost savings and synergies.

The pharmaceutical industry is highly competitive, with a few major players dominating the market. GSK's primary competitors include Pfizer, Johnson & Johnson and Roche. The industry is also heavily regulated, with stringent drug safety and efficacy requirements.

One of the key trends in the industry is the shift toward personalized medicine, which involves developing treatments tailored to individual patients based on their genetic makeup. GSK has invested heavily in this area, focusing on oncology and rare diseases.

Despite the pharmaceutical industry's challenges, GSK has several growth opportunities in its core business areas. The company has a strong pipeline of new drugs and vaccines in development, including several potential blockbusters. GSK is also expanding its presence in emerging markets, where demand for healthcare products is growing rapidly.

In addition, the company has been exploring opportunities in digital health and artificial intelligence, which could transform how medicines are developed and delivered. GSK is also committed to sustainability and has set ambitious targets to reduce its environmental impact and improve access to healthcare in low-income countries.

The pharmaceutical industry is subject to a range of risks and challenges, including regulatory hurdles, patent expirations and intense competition. GSK is not immune to these risks and faces some specific challenges.

The COVID-19 pandemic is one of the biggest challenges facing GSK. Another risk is the potential for increased regulatory scrutiny. The pharmaceutical industry is pressured to demonstrate that its products are safe and effective. GSK has faced significant fines and penalties for regulatory violations.

GSK faces competition from established players in the industry and new entrants, particularly in digital health. As a result, the company will need to continue to invest in innovation and R&D to maintain its competitive position and drive growth in the future.

Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Stock News Headlines

March 25, 2023 | americanbankingnews.com
GSK plc (NYSE:GSK) Receives $1,533.00 Consensus Target Price from Analysts
March 20, 2023 | americanbankingnews.com
GSK (NYSE:GSK) Upgraded at Deutsche Bank Aktiengesellschaft
March 27, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
March 14, 2023 | finance.yahoo.com
GSK and Earvin "Magic" Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
March 11, 2023 | finance.yahoo.com
3 High Dividend Healthcare Stocks for Passive Income
March 5, 2023 | finance.yahoo.com
Could This Be the Next Blockbuster Vaccine for This Big Pharma Stock?
March 1, 2023 | finance.yahoo.com
UPDATE 1-GSK catches up with Pfizer in RSV vaccine race after FDA panel's backing
February 24, 2023 | finance.yahoo.com
UPDATE 1-First Zantac cancer risk trial in Calif. postponed five months
March 27, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
February 24, 2023 | finance.yahoo.com
GSK's Relief For Few Months, First Trial Claiming Zantac Caused Cancer Pushed Into Late 2023
February 16, 2023 | finance.yahoo.com
UPDATE 1-Judge weighs key evidence ahead of first Zantac cancer trial
February 16, 2023 | finance.yahoo.com
Judge to weigh key evidence ahead of first Zantac cancer trial
February 10, 2023 | finance.yahoo.com
US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer
February 2, 2023 | finance.yahoo.com
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod
February 2, 2023 | finance.yahoo.com
GSK plc (NYSE:GSK) Q4 2022 Earnings Call Transcript
February 1, 2023 | finance.yahoo.com
GSK Posts Higher Q4 Sales, Profits, With Record Sales From Shingles Vaccine
February 1, 2023 | uk.finance.yahoo.com
FTSE 100: GSK tops forecasts after strong sales of shingles vaccine
January 31, 2023 | finance.yahoo.com
Advil Maker Haleon Said to Study Potential Deals to Bulk Up
January 26, 2023 | marketwatch.com
GSK falls Tuesday, underperforms market
January 26, 2023 | marketwatch.com
GSK rises Wednesday, outperforms market
January 17, 2023 | finance.yahoo.com
UPDATE 1-Moderna says RSV vaccine 84% effective at preventing symptoms in older adults
January 10, 2023 | finance.yahoo.com
GSK quadruples space in Alewife lab building with new lease
January 9, 2023 | stocknews.com
3 Must Have Pharma Stocks in January 2023
December 30, 2022 | finance.yahoo.com
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
December 24, 2022 | msn.com
Why I’d buy GSK shares in 2023
December 24, 2022 | seekingalpha.com
GSK, Sanofi COVID booster vaccine gets approval in UK
December 17, 2022 | msn.com
Masterplan to guide future development of GSK site now complete
See More Headlines
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Company Calendar

Last Earnings
2/02/2021
Ex-Dividend for 1/12 Dividend
11/17/2022
Dividend Payable
1/12/2023
Ex-Dividend for 4/13 Dividend
2/23/2023
Today
3/27/2023
Dividend Payable
4/13/2023
Next Earnings (Estimated)
4/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:GSK
CUSIP
N/A
CIK
1131399
Web
www.gsk.com
Phone
442080475000
Fax
44-20-8047-7807
Employees
90,096
Year Founded
2000

Profitability

EPS (Most Recent Fiscal Year)
$8.58
Trailing P/E Ratio
4.01
Forward P/E Ratio
9.77
P/E Growth
1.77
Net Income
$18.50 billion
Net Margins
43.75%
Pretax Margin
19.19%
Return on Equity
36.37%
Return on Assets
7.85%

Debt

Debt-to-Equity Ratio
1.69
Current Ratio
0.91
Quick Ratio
0.68

Sales & Book Value

Annual Sales
$36.28 billion
Price / Sales
2.04
Cash Flow
$4.35 per share
Price / Cash Flow
7.90
Book Value
$5.79 per share
Price / Book
5.94

Miscellaneous

Outstanding Shares
2,155,670,000
Free Float
1,940,105,000
Market Cap
$74.11 billion
Optionable
Optionable
Beta
0.65

Social Links


Key Executives

  • Emma N. WalmsleyEmma N. Walmsley
    Chief Executive Officer & Executive Director
  • Iain James MackayIain James Mackay
    Chief Financial Officer & Executive Director
  • Tony Wood
    Chief Scientific Officer
  • Shobie Ramakrishnan
    Chief Digital & Technology Officer
  • Amy Altshul
    SVP-Legal, Research & Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













GSK Stock - Frequently Asked Questions

Should I buy or sell GSK stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 3 sell ratings, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings or view top-rated stocks.

How have GSK shares performed in 2023?

GSK's stock was trading at $35.14 at the beginning of the year. Since then, GSK stock has decreased by 2.2% and is now trading at $34.38.
View the best growth stocks for 2023 here.

Are investors shorting GSK?

GSK saw a drop in short interest in the month of February. As of February 28th, there was short interest totaling 2,880,000 shares, a drop of 23.0% from the February 13th total of 3,740,000 shares. Based on an average daily volume of 4,660,000 shares, the short-interest ratio is currently 0.6 days. Currently, 0.1% of the shares of the stock are sold short.
View GSK's Short Interest.

When is GSK's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our GSK earnings forecast.

How were GSK's earnings last quarter?

GSK plc (NYSE:GSK) issued its earnings results on Tuesday, February, 2nd. The pharmaceutical company reported $0.62 EPS for the quarter, missing the consensus estimate of $0.64 by $0.02. The pharmaceutical company had revenue of $8.74 billion for the quarter, compared to analysts' expectations of $8.71 billion. GSK had a net margin of 43.75% and a trailing twelve-month return on equity of 36.37%. The firm's revenue was down 1.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.39 earnings per share.
Read the conference call transcript.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK announced a quarterly dividend on Wednesday, February 1st. Investors of record on Friday, February 24th will be paid a dividend of $0.3404 per share on Thursday, April 13th. This represents a $1.36 dividend on an annualized basis and a yield of 3.96%. The ex-dividend date of this dividend is Thursday, February 23rd.
Read our dividend analysis for GSK.

What ETFs hold GSK's stock?

ETFs with the largest weight of GSK (NYSE:GSK) stock in their portfolio include VanEck Pharmaceutical ETF (PPH), Sound Equity Income ETF (SDEI), Pacer BioThreat Strategy ETF (VIRS), Altrius Global Dividend ETF (DIVD), Pacer Developed Markets International Cash Cows 100 ETF (ICOW), ALPS Hillman Active Value ETF (HVAL), Pacer Global Cash Cows Dividend ETF (GCOW) and B.A.D. Etf (BAD).

Is GSK a good dividend stock?

GSK (NYSE:GSK) pays an annual dividend of $1.33 per share and currently has a dividend yield of 3.78%. The dividend payout ratio is 15.50%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 36.04% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GSK.

What guidance has GSK issued on next quarter's earnings?

GSK issued an update on its FY 2023 earnings guidance on Wednesday, February, 1st. The company provided earnings per share (EPS) guidance of $1.94-$1.99 for the period, compared to the consensus earnings per share estimate of $3.64. The company issued revenue guidance of $38.54 billion-$39.27 billion, compared to the consensus revenue estimate of $35.92 billion.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

What is GSK's stock symbol?

GSK trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GSK's major shareholders?

GSK's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include JTC Employer Solutions Trustee Ltd (0.88%), Arrowstreet Capital Limited Partnership (0.69%), Fisher Asset Management LLC (0.62%), Price T Rowe Associates Inc. MD (0.57%), Renaissance Technologies LLC (0.31%) and Morgan Stanley (0.25%).
View institutional ownership trends.

How do I buy shares of GSK?

Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GSK's stock price today?

One share of GSK stock can currently be purchased for approximately $34.38.

How much money does GSK make?

GSK (NYSE:GSK) has a market capitalization of $74.11 billion and generates $36.28 billion in revenue each year. The pharmaceutical company earns $18.50 billion in net income (profit) each year or $8.58 on an earnings per share basis.

How many employees does GSK have?

The company employs 90,096 workers across the globe.

How can I contact GSK?

GSK's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The official website for the company is www.gsk.com. The pharmaceutical company can be reached via phone at 442080475000, via email at gsk.investor-relations@gsk.com, or via fax at 44-20-8047-7807.

This page (NYSE:GSK) was last updated on 3/27/2023 by MarketBeat.com Staff